![]() |
市场调查报告书
商品编码
1930128
尿失禁治疗器材市场规模、占有率、成长及全球产业分析:按类型、应用和地区划分的洞察,2026-2034Urinary Incontinence Devices Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034 |
||||||
预计未来十年,全球尿失禁治疗器材市场将稳定成长,这主要得益于公众意识的提高、技术创新以及慢性病发病率的上升。根据 Fortune Business Insights 预测,该市场规模预计在 2025 年达到 45.3 亿美元,2026 年将成长至 47 亿美元,到 2034 年将达到 74.8 亿美元,预测期内复合年增长率 (CAGR) 为 6.0%。北美地区将在 2025 年占市场主导地位,市场占有率将达到 42.5%,这反映了该地区先进的医疗保健基础设施、有利的报销政策以及积极的技术应用。
尿失禁护理装置有助于预防尿液渗漏,提高舒适度,增强行动能力和独立性,尤其对老年人而言。由于糖尿病、肥胖、泌尿道感染和神经系统疾病等疾病的盛行率不断上升,全球对这些装置的需求正在增加。例如,根据ScienceDirect发布的2025年数据,约有40%的欧洲人口患有尿失禁。包括Coloplast A/S、ConvaTec和Essity Actiebolag在内的领先企业正积极投入研发,致力于开发旨在改善病患照护的创新先进产品。
市场动态
成长驱动因素
急性和慢性疾病发生率的上升以及人口老化是市场成长的关键驱动因素。根据美国国家生物技术资讯中心 (NCBI) (2025) 的数据,全球尿失禁盛行率约为 32.4%,凸显了对有效解决方案的广泛需求。公众意识的提高、社会歧视的减少以及更完善的医保报销政策正在进一步推动这些产品的普及。预计到 2030 年,全球六分之一的人口将超过 60 岁,这将支撑对这些医疗器材的长期需求。
限制因子
在巴西、中国和印度等发展中国家,有限的诊断能力和健保报销政策制约了市场成长。患者就诊较晚以及缺乏慢性病方面的临床专业知识会导致诊断和治疗延误。例如,巴西的公共医疗体係不涵盖急迫性尿失禁的药物治疗,限制了该地区病患获得先进医疗器材的机会。
机会
可吸收和不可吸收产品(智慧感测器、行动应用程式、非侵入式神经调节设备等)的技术创新正在重塑市场格局。例如,UroMems公司于2025年2月宣布,接受其UroActive智慧植入物治疗的女性患者达到了六个月的主要终点,证明了其临床疗效。这些进展为大型公司提供了拓展产品组合、满足患者未被满足的需求的机会。
挑战
设备成本高昂,尤其是在新兴市场,是其广泛应用的一大障碍。尿失禁吊带的价格从10美元到超过10,000美元不等,限制了患者的取得途径。其他挑战包括手术风险、器械故障、监管障碍以及来自行为疗法和药物疗法等替代疗法的竞争。
市场趋势
一个显着的趋势是向微创手术的转变,其驱动因素是恢復时间更短、疼痛更轻、住院时间更短。中段尿道吊带和机器人辅助平台等技术正日益受到关注。根据国际尿控协会 (ICS) 2024 年的一项研究,中段尿道吊带植入术后一年的再次手术率仅为 0.8%,五年的再次手术率仅为 2.7%,这表明治疗效果和患者满意度均有所提高。
依产品类型
市场分为吸收性产品和非吸收性产品。预计到 2026 年,吸收性产品(包括内裤、三角裤、护垫和床垫保护垫)将占市场占有率的 67.02%。非吸收性产品包括吊带、导尿管、尿道插入物、刺激装置和引流袋。
性别
由于女性尿失禁的高发生率,女性市场将在 2026 年占主导地位,市场占有率将达到 64.89%。根据 Phoenix Physical Therapy 2025 年的数据,美国 18 岁以上女性中,四分之一患有某种形式的尿失禁。预计男性市场在预测期内的复合年增长率将达到 4.9%。
按应用
由于其便利性和卫生优势,一次性尿失禁产品将在 2026 年占市场主导地位,市场占有率将达到 58.3%。可重复使用产品预计将以 5.4% 的复合年增长率成长。
依最终使用者划分
家庭医疗保健将在 2025 年占市场主导地位,预计到 2026 年将占 44.47% 的市场占有率,这主要得益于患者对家庭护理的偏好以及充足的报销政策。医院和门诊手术中心 (ASC) 预计将以 5.7% 的复合年增长率成长。
The global urinary incontinence devices market is poised for steady growth in the coming decade, driven by rising awareness, technological innovations, and increasing prevalence of chronic conditions. According to Fortune Business Insights, the market was valued at USD 4.53 billion in 2025 and is projected to grow to USD 4.7 billion in 2026, eventually reaching USD 7.48 billion by 2034, representing a CAGR of 6.0% during the forecast period. In 2025, North America dominated the market with a 42.5% share, reflecting the region's advanced healthcare infrastructure, favorable reimbursement policies, and strong technological adoption.
Urinary incontinence devices help prevent urine leakage, improve comfort, and enhance mobility and independence, particularly among the aging population. The rising prevalence of conditions such as diabetes, obesity, urinary tract infections, and neurological disorders is increasing the demand for these devices globally. For example, as per 2025 data published by ScienceDirect, approximately 40% of the population in Europe suffers from urinary incontinence. Key players including Coloplast A/S, Convatec Inc., and Essity Aktiebolag are actively focusing on R&D initiatives to develop innovative and technologically advanced products to enhance patient care.
Market Dynamics
Drivers
The growing incidence of acute and chronic diseases, coupled with an aging population, is a major driver of market growth. According to the NCBI (2025), the global prevalence of urinary incontinence was around 32.4%, highlighting the widespread need for effective solutions. Rising awareness, reduced stigma, and better reimbursement policies further encourage adoption. By 2030, one in six people globally is expected to be aged 60 or above, supporting the long-term demand for these devices.
Restraints
Market growth is constrained by limited diagnosis and reimbursement policies in developing nations, particularly in Brazil, China, and India. Delayed referrals and a lack of clinical expertise in chronic conditions result in postponed diagnosis and treatment. For instance, the Brazilian Public Health System does not cover pharmacotherapy for urge urinary incontinence, limiting access to advanced devices in the region.
Opportunities
Technological innovations in absorbent and non-absorbent products, including smart sensors, mobile apps, and non-invasive neuromodulation devices, are reshaping the market. For example, in February 2025, UroMems announced that female patients treated with UroActive Smart Implants successfully reached six-month primary endpoints, demonstrating clinical effectiveness. These advancements provide opportunities for key players to expand their portfolios and address unmet patient needs.
Challenges
High device costs hinder adoption, especially in emerging economies. Urinary incontinence slings range from USD 10 to over USD 10,000, limiting patient access. Additional challenges include surgical risks, device failures, regulatory hurdles, and competition from alternative treatments like behavioral therapy or pharmacological options.
Market Trends
A notable trend is the shift toward minimally invasive surgeries, driven by faster recovery, reduced pain, and shorter hospital stays. Technologies such as mid-urethral slings and robotic-assisted platforms are gaining traction. According to a 2024 study by the International Continence Society, mid-urethral sling insertions showed reoperation rates of only 0.8% at one year and 2.7% at five years, highlighting improved outcomes and patient satisfaction.
By Product Type
The market is segmented into absorbents and non-absorbents, with absorbents-including underwear, briefs, pads, and bed protectors-dominating 67.02% of the market in 2026. Non-absorbent products include slings, catheters, urethral inserts, stimulation devices, and drainage bags.
By Gender
The female segment dominated in 2026 with a 64.89% share, due to higher prevalence rates among women. According to 2025 Phoenix Physical Therapy data, one in four women over 18 in the U.S. experiences some form of urinary incontinence. The male segment is projected to grow at a CAGR of 4.9% during the forecast period.
By Usage
The disposable segment led in 2026 with 58.3% share, driven by convenience and hygiene benefits. Reusable products are expected to grow at a CAGR of 5.4%.
By End User
Homecare settings dominated in 2025, with an anticipated 44.47% market share in 2026, due to patient preference for at-home treatment and adequate reimbursement policies. Hospitals and ASCs are projected to grow at a CAGR of 5.7%.
Competitive Landscape
The market is highly competitive, led by Essity Aktiebolag, Medtronic, Coloplast A/S, BD, Teleflex, and Johnson & Johnson, who focus on product innovation, regulatory approvals, and geographic expansion. Notable developments include:
Conclusion
The global urinary incontinence devices market is projected to grow from USD 4.53 billion in 2025 to USD 7.48 billion by 2034, driven by rising prevalence of chronic conditions, technological advancements, and homecare adoption. While challenges such as high device costs and limited reimbursement in emerging markets persist, innovations in minimally invasive devices, smart sensors, and patient-centric solutions are expected to significantly expand market penetration and improve patient outcomes worldwide.
Segmentation By Product Type, Gender, Usage, End User, and Region
By Product Type * Absorbents
By Gender * Male
By Usage * Reusable
By End User * Hospitals & ASCs
By Region * North America (By Product Type, Gender, Usage, End User, and Country)